ANGIOVIST 292 Drug Patent Profile
✉ Email this page to a colleague
When do Angiovist 292 patents expire, and what generic alternatives are available?
Angiovist 292 is a drug marketed by Bayer Hlthcare and is included in one NDA.
The generic ingredient in ANGIOVIST 292 is diatrizoate meglumine; diatrizoate sodium. There are eleven drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the diatrizoate meglumine; diatrizoate sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Angiovist 292
A generic version of ANGIOVIST 292 was approved as diatrizoate meglumine; diatrizoate sodium by ANDA REPOSITORY on June 27th, 2022.
Summary for ANGIOVIST 292
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 5 |
| Patent Applications: | 190 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | ANGIOVIST 292 at DailyMed |
US Patents and Regulatory Information for ANGIOVIST 292
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer Hlthcare | ANGIOVIST 292 | diatrizoate meglumine; diatrizoate sodium | INJECTABLE;INJECTION | 087724-001 | Sep 23, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
